HK1222565A1 - 高效糖皮質激素 - Google Patents

高效糖皮質激素 Download PDF

Info

Publication number
HK1222565A1
HK1222565A1 HK16110801.0A HK16110801A HK1222565A1 HK 1222565 A1 HK1222565 A1 HK 1222565A1 HK 16110801 A HK16110801 A HK 16110801A HK 1222565 A1 HK1222565 A1 HK 1222565A1
Authority
HK
Hong Kong
Prior art keywords
compound
group
alkyl
heteroaryl
aryl
Prior art date
Application number
HK16110801.0A
Other languages
English (en)
Chinese (zh)
Inventor
Huaqiang Eric Xu
Yuanzheng He
Karsten Melcher
Wei Yi
Jingjing Shi
Original Assignee
范安德尔研究所
中国科学院上海药物研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 范安德尔研究所, 中国科学院上海药物研究所 filed Critical 范安德尔研究所
Publication of HK1222565A1 publication Critical patent/HK1222565A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036—Nitrogen-containing hetero ring
    • C07J71/0042—Nitrogen only
    • C07J71/0047—Nitrogen only at position 2(3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Epidemiology (AREA)
HK16110801.0A 2013-09-25 2014-09-25 高效糖皮質激素 HK1222565A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361882444P 2013-09-25 2013-09-25
US61/882,444 2013-09-25
PCT/US2014/057497 WO2015048316A1 (en) 2013-09-25 2014-09-25 Highly potent glucocorticoids

Publications (1)

Publication Number Publication Date
HK1222565A1 true HK1222565A1 (zh) 2017-07-07

Family

ID=52744465

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16110801.0A HK1222565A1 (zh) 2013-09-25 2014-09-25 高效糖皮質激素

Country Status (9)

Country Link
US (1) US9975918B2 (enExample)
EP (1) EP3049089B1 (enExample)
JP (1) JP2016531852A (enExample)
KR (1) KR20160060688A (enExample)
CN (2) CN113845558A (enExample)
AU (1) AU2014324961A1 (enExample)
ES (1) ES2751457T3 (enExample)
HK (1) HK1222565A1 (enExample)
WO (1) WO2015048316A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE055199T2 (hu) 2015-07-06 2021-11-29 Sage Therapeutics Inc Oxiszterolok és alkalmazási eljárásaik
MD3319611T2 (ro) 2015-07-06 2021-06-30 Sage Therapeutics Inc Oxisteroli și metode de utilizare a acestora
PT3436022T (pt) 2016-04-01 2022-07-04 Sage Therapeutics Inc Oxisteróis e métodos de utilização dos mesmos
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11149056B2 (en) 2016-09-30 2021-10-19 Sage Therapeutics, Inc. C7 substituted oxysterols and methods of use thereof
WO2018071736A1 (en) * 2016-10-14 2018-04-19 Van Andel Research Institute Structures and mechanism for the design of highly potent glucocorticoids
EP4105223B1 (en) 2016-10-18 2025-04-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
RU2019115113A (ru) 2016-10-18 2020-11-24 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
US11091447B2 (en) 2020-01-03 2021-08-17 Berg Llc UBE2K modulators and methods for their use
CN117024499A (zh) * 2023-07-17 2023-11-10 陕西汉江药业集团股份有限公司 在2位引入亚甲基羟基的甾体化合物制备方法
WO2025157225A1 (zh) * 2024-01-24 2025-07-31 浙江柏拉阿图医药科技有限公司 一种高效力糖皮质激素化合物及其制备和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4049813A (en) 1976-07-15 1977-09-20 Sandoz, Inc. Substituted isoxazolo pyridinones
CA2451057A1 (en) 2001-06-14 2002-12-27 Banyu Pharmaceutical Co., Ltd. Novel isoxazolopyridone derivatives and use thereof
GB0119911D0 (en) 2001-08-15 2001-10-10 Novartis Ag Organic Compounds
BRPI0817941A2 (pt) * 2007-10-04 2015-05-05 Astrazeneca Ab Compostos de pirazol de [3,2-c] esteroidais, com atividade glucocorticóide
WO2010083218A1 (en) 2009-01-13 2010-07-22 Van Andel Research Institute Methods of using substituted isoxazolo pyridinones as dissociated glucocorticoids
UY32523A (es) * 2009-04-03 2010-10-29 Astrazeneca Ab Compuestos que tienen actividad agonista del receptor de glucocorticosteroides
UY32525A (es) * 2009-04-03 2010-10-29 Astrazeneca Ab Compuestos que tienen actividad agonista del receptor de glucocorticosteroides
AU2010260177A1 (en) * 2009-06-16 2011-12-15 Merck Sharp & Dohme Corp. Novel [3,2-c] heteroaryl steroids as glucocorticoid receptor agonists, compositions and uses thereof

Also Published As

Publication number Publication date
EP3049089B1 (en) 2019-08-21
US20160251393A1 (en) 2016-09-01
CN105744937A (zh) 2016-07-06
JP2016531852A (ja) 2016-10-13
EP3049089A1 (en) 2016-08-03
US9975918B2 (en) 2018-05-22
AU2014324961A8 (en) 2016-04-21
EP3049089A4 (en) 2017-08-09
ES2751457T3 (es) 2020-03-31
WO2015048316A1 (en) 2015-04-02
CN113845558A (zh) 2021-12-28
KR20160060688A (ko) 2016-05-30
AU2014324961A1 (en) 2016-04-14

Similar Documents

Publication Publication Date Title
HK1222565A1 (zh) 高效糖皮質激素
CN101454005B (zh) 用于治疗代谢性炎症介导的疾病的噻唑烷二酮类似物
JP5634526B2 (ja) 代謝性疾患を処置するためのｐｐａｒ温存チアゾリジンジオン塩
JP6689856B2 (ja) ６，７−ジヒドロピラゾロ［１，５−ａ］ピラジン−４（５Ｈ）−オン化合物およびＭＧＬＵＲ２受容体の負のアロステリック調節因子としてのそれらの使用
KR20220101075A (ko) Il-17a 조절인자 및 이의 용도
UA121658C2 (uk) Сполуки 5-хлордифторметоксифенілпіразолопіримідину як інгібітори янус-кінази
CN106008488B (zh) 氰基吲哚类衍生物及其制备方法和用途
EP3174882B1 (en) 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglu2 receptors
CA3237467A1 (en) Lactams as cbl-b inhibitors selective over c-cbl
JP2022132464A (ja) 非常に強力な糖質コルチコイドの構造およびデザインのための機構
CN105308037A (zh) 三唑化合物及其作为γ分泌酶调节剂的用途
JP2014515741A (ja) オーレオバシジウム誘導体および合成方法
TW201629025A (zh) 化合物及其作為ｂａｃｅ抑制劑之用途
HK40070300A (en) Highly potent glucocorticoids
CN107089955B (zh) 磺酰胺类衍生物及其制备方法和用途
HK40017057A (en) Structures and mechanism for the design of highly potent glucocorticoids
HK40017057B (zh) 用於设计高效力糖皮质激素的结构与机制
WO2025157225A1 (zh) 一种高效力糖皮质激素化合物及其制备和用途
WO2025050846A1 (zh) 一种化合物、及其药物组合物和应用